仑伐替尼治疗放射性碘难治性分化型甲状腺癌研究进展  

Treatment of radioactive iodine-refractory differentiated thyroid cancer with lenvatinib:research advances

作　　者：付冉 王小楠 丁琮洋 崔艳军 范理菊 董占军[2] FU Ran;WANG Xiao-nan;DING Cong-yang;CUI Yan-jun;FAN Li-ju;DONG Zhan-jun(Graduate School of Hebei Medical University,Shijiazhuang 050017,China;Department of Pharmacy,Hebei General Hospital,Shijiazhuang 050051,China)

机构地区：[1]河北医科大学研究生学院,石家庄050017 [2]河北省人民医院药学部,石家庄050051

出　　处：《国际药学研究杂志》2020年第12期1094-1097,1103,共5页Journal of International Pharmaceutical Research

基　　金：2018年度河北省医学科学研究重点课题计划(20180008)。

摘　　要：仑伐替尼是一种多靶点酪氨酸激酶抑制剂,可作用于血管内皮生长因子受体(VEGFR)及成纤维细胞生长因子受体(FGFR)等多个靶点抑制血管生成进而阻断肿瘤的生长,经美国FDA批准用于放射性碘难治性分化型甲状腺癌(RRDTC)的治疗。本文对仑伐替尼治疗RR-DTC的作用机制及其在RR-DTC中的有效性、安全性、经济性等多方面进行总结,为仑伐替尼的临床合理用药提供参考。Lenvatinib is a kind of multi-receptor tyrosine kinase inhibitor which can inhibit tumor growth by inhibiting targets such as vascular endothelial growth factor receptor(VEGFR)and fibroblast growth factor receptor(FGFR).It has already been approved by FDA for the treatment of radioactive iodine-refractory differentiated thyroid cancer(RR-DTC).In this paper,the mecha⁃nism of action and the efficacy,safety and economy of lenvatinib in the treatment of RR-DTC are summarized to provide reference for the rational clinical use of lenvatinib.

关 键 词：仑伐替尼 放射性碘难治性分化型甲状腺癌 研究进展 

分 类 号：R96[医药卫生—药理学]